Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 8, 2003, Pages 1071-1079

  Brooks, David J ^a   Sagar, H ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; SELEGILINE; TOLCAPONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FALLING; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO;

EID: 0041704637     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.8.1071     Document Type: Article

References (44)

1. Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998;351:1221-2.
2. Agid Y, Ahlskog E, Albanese A, Members of the Consensus Meeting. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999;14:911-13.
3. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
4. Marsden CD, Parkes JD. "ON-off" effects in patients with Parkinson's disease on chronic levodapa therapy. Lancet 1976;i:292-6.
5. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
6. Block G, Liss C, Reines S, and the CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur Neurol 1997;37:23-7.
7. Larsen JP, Karlsen K, Tandberg E. Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study. Mov Disord 2000;5:826-9.
8. Schapira AHV, Obeso JA, Olanow CW. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 2000;55(suppl 4):65-8.
9. Waters C. Catechol-O-methytransferase (COMT) inhibitors in Parkinson's disease. J Am Geriatric Soc 2000;48:692-8.
10. Koller WC, Hutton JT, Tolosa E, and the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-19.
11. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):25-38.
12. Hutton J, Morris J. Therapeutic advances of sustained release levodopa formulation. CNS Drugs 1994;2:110-19.
13. Pahwa R, Lyons K, McGuire D, et al. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 1997;12:677-81.
14. Kaakkola S, Gordin A, Männistö P. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994;25:813-24.
15. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-50.
16. Nissinen E, Linden IB, Schultz E, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992;346:262-6.
17. Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 1999;81:1-36.
18. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
19. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-9.
20. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-19.
21. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-96.
22. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-33.
23. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
24. Baas H, Zehrden F, Seizer R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokin 2001;40:383-93.
25. Karlsen KH, Tandberg E, Årsland D, et al. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584-9.
26. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease. Neurology 1997;49:665-71.
27. Suchowersky O, Bailey P, Pourcher E, et al. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin Neuropharmacol 2001;24:214-20.
28. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
29. Rinne UK, Larsen JP, Siden Å, and the Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14.
30. Myllylä VV, Kultalahti E-R, Haapaniemi H, and the Filomen Study Group. Twelve-months safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.
31. Poewe W, Deuschl G, Gordin A, and the Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-months randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:1-11.
32. Fahn S, Elton R, and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, et al, eds. Recent developments in Parkinson's disease. Florom Park: Macmillan, 1987:153-63.
33. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-8.
34. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-7.
35. Myllylä W, Jackson M, Larsen JP, et al. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 1997;4:333-41.
36. Rajput AH, Martin W, Sainthilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
37. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998;55:1089-95.
38. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995;2:341-7.
39. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-94.
40. Committee for Proprietary Medicinal Products (CPMP). European Economic Community. Note for guidance: clinical investigation of medicinal products in the treatment of Parkinson's disease. Eur Neuropsychopharmacol 1999;9:443-9.
41. Hobson JP, Edwards NI, Meara RJ. The Parkinson's disease Activities of Daily Living scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clin Rehabil 2001;15:241-6.
42. Jenkinson C, Fitzpatrick R, Peto V. Health related quality-of-life measurement in patients with Parkinson's disease. Pharmacoeconomics 1999;15:157-65.
43. Durif F, Devaux J-J, Pere J-J et al. Efficacy and tolerability of entacapone as an adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45:111-18.
44. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease. Implications for the early use of COMT inhibitors. Neurology 2000;55(suppl 4):72-7.